EnGeneIC performs research, development and manufacturing of targeted anti-cancer therapies.
EDV™ Technology Stimulates Both Innate and Adaptive Immune Response and Confers Long-Term Survival
Abstract Demonstrates Promising Early Results from Phase I/IIa study in Patients with Recurrent, Metastatic Pancreatic Cancer.